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Abstract  
 
One means of improving healthcare workers' knowledge of and attitudes to vaccines is through running vaccine conferences which are accessible, 
affordable, and relevant to their everyday work. Various vaccinology conferences are held each year worldwide. These meetings focus heavily on 
basic science with much discussion about new developments in vaccines, and relatively little coverage of policy, advocacy, and communication 
issues. A negligible proportion of delegates at these conferences come from Africa, home to almost 40% of the global burden of vaccine-
preventable diseases. To the best of our knowledge, no major vaccinology conference has ever been held on the African continent apart from 
World Health Organization (WHO) meetings. The content of the first International African Vaccinology Conference was planned to be different; to 
focus on the science, with a major part of discussions being on clinical, programmatic, policy, and advocacy issues. The conference was held in 
Cape Town, South Africa, from 8 to 11 November 2012. The theme of the conference was “Advocating for efforts to protect African children, 
families, and communities from the threat of infectious diseases”. There were more than 550 registered participants from 55 countries (including 
37 African countries). There were nine pre-conference workshops, ten plenary sessions, and 150 oral and poster presentations. The conference 
discussed the challenges to universal immunisation in Africa as well as the promotion of dialogue and communication on immunisation among all 
stakeholders. There was general acknowledgment that giant strides have been made in Africa since the global launch of the Expanded Programme 
on Immunisation in 1974. For example, there has been significant progress in introducing new and under-utilised vaccines; including hepatitis 
B, Haemophilus influenza type b, pneumococcal conjugate, rotavirus, meningococcal A conjugate, and human papillomavirus vaccines. In May 
2012, African countries endorsed the Global Vaccine Action Plan at the World Health Assembly. However, more than six million children remain 
incompletely vaccinated in Africa leading to more than one million vaccine-preventable deaths annually. In addition, there are persistent problems 
with leadership and planning, vaccine stock management, supply chain capacity and quality, provider-parent communication, and financial 
sustainability. The conference delegates agreed to move from talking to taking concrete actions around children's health, and to ensure that 
African governments commit to saving children's lives. They would advocate for lower costs of immunisation programmes in Africa, perhaps 
through bulk buying and improved administration of vaccine rollout through the New Partnership for Africa's Development. 
 
 
 
 
 
Introduction 
 
In May 2012 African countries joined other member states of the 
World Health Assembly to endorse the Global Vaccine Action Plan 
(GVAP), an agenda to avert millions of vaccine-preventable deaths 
by 2020 through impartial access to existing vaccines for people in 
every community around the world [1]. At the time of endorsing the 
GVAP, despite substantial improvements with immunisation 
programmes in Africa, there were persistent problems with 
leadership and planning, vaccine stock management, supply chain 
capacity and quality, provider-parent communication, and financial 
sustainability [2]. Childhood immunisation coverage varied widely 
between and within African countries, and more than seven million 
children on the continent did not receive the full series of vaccines 
in their national immunisation schedule [3]. The consequences of 
low immunisation coverage include the premature deaths of more 
than one million children each year in Africa [4]. Many reasons have 
been proposed as to why vaccination coverage in African children is 
low [3,5,6]. These include inconsistent policies, poor understanding 
of diseases, poverty, and cultural issues. Other factors which have 
been blamed include parental apathy or ignorance and high cost of 
vaccines. In addition, the fragmented nature of healthcare systems 
in some countries, with children´s records scattered among many 
providers they might see during the time they were supposed to 
receive their vaccines, may lead to missed opportunities to 
vaccinate. Having a forum such as a vaccinology conference with 
delegates from all African countries, will allow dialogue to identify 
the biggest challenges faced and opportunities to identify solutions 
employed by other countries. One means of improving healthcare 
workers' knowledge of and attitudes to existing vaccines is through 
running vaccinology conferences which are accessible, affordable 
and relevant to their everyday work. Each year various international 
vaccinology conferences are organised around the world 
(http://www.isv-online.org/). However, the focus of these meetings 
is heavily on basic science, with much discussion about new 
developments in vaccines, but relatively little coverage of policy, 
advocacy, and communication issues. The meetings attract 
delegates mainly from Europe and North America. For example, at 
the 2011 International Society for Vaccines Annual Congress 
(http://isvcongress.org/programme/5th-isv-annual-congress-
program), less than 3% of participants were from Africa (home to 
over 15% of the world's population and where almost 40% of the 
burden of vaccine preventable diseases occurs). To the best of our 
knowledge, no major vaccinology conference has ever been held on 
the African continent apart from World Health Organization (WHO) 
meetings. We therefore proposed the International African 
Vaccinology Conference, whose content would be different from the 
others. While the meeting would focus on the science a major part 
of the discussions would be on clinical, programmatic, policy, and 
advocacy issues. 
  
  
Conference outlines and outcomes 
 
The first International African Vaccinology Conference took place in 
Cape Town, South Africa, from 8 to 11 November 2012.The 
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objectives of the conference were to discuss challenges and 
obstacles to achieving universal childhood immunisation coverage in 
Africa, to identify and open dialogue with all immunisation 
stakeholders on the continent, and to promote communication 
between countries in Africa. The conference was organised by the 
Vaccines for Africa Initiative based at the University of Cape Town, 
and the National Institute for Communicable Diseases, a branch of 
the (South African) National Health Laboratory Service. It brought 
together healthcare workers; immunisation programme staff; 
researchers; civil society (including Médecins Sans Frontières); 
United Nations' agencies (World Health Organization, United Nations 
Children's Fund); international organisations(Malaria Vaccine 
Initiative, PATH, International AIDS Vaccine Initiative, Agence de 
Medecine Preventive, Bill and Melinda Gates Foundation); private-
public partnerships (Global Alliance for Vaccines and Immunization, 
Biovac Institute, Polio Research Foundation); industry 
(GlaxoSmithKline, Sanofi Pasteur, MSD, Pfizer, and Emergent 
Biosolutions); product development partners (Aeras Global TB 
Vaccine Initiative); national regulatory agencies; and government 
agencies (Centers for Disease Control and Prevention, National 
Institutes of Health). The conference was held at the Lagoon Beach 
Hotel and Conference in Cape Town, South Africa. There were 572 
registered participants from 37 African countries as well as 
delegates from countries in the Americas, Asia, Australia, and 
Europe. The official language of the conference was English, with 
simultaneous translation to French. The conference was preceded 
by nine pre-conference workshops. This included society meetings: 
the Foundation launch of the African Paediatric Infectious Diseases 
Society (AfPIDS), the 7th African Rotavirus Symposium, and the 
Influenza in Africa workshop [7]. Other workshops addressed 
essential vaccine issues in Africa: surveillance of adverse events 
following immunisation; communication, advocacy and social 
mobilisation; role of partially effective vaccines; evidence-based 
approaches to immunisation policies; and national immunisation 
technical advisory groups (NITAGs). The conference also hosted 
industry-sponsored workshops which covered a wide range of 
topics, including: pneumococcal, human papilloma virus (HPV), 
dengue, influenza, rotavirus, and tuberculosis (TB) vaccines. 
Emerging African researchers were offered an opportunity to show 
case their work. One hundred and thirty four abstracts were 
submitted by emerging African researchers and 118 were selected 
for presentation: 37 oral papers, and 81 poster presentations. They 
covered a comprehensive set of topics relevant to immunisation 
programmes in Africa, including: ethics, operational issues, 
surveillance, existing vaccines, and the vaccine pipeline (particularly 
for TB and malaria vaccines). There were ten plenary sessions, 
namely: progress towards reaching the Millennium Development 
Goals (MDGs), vaccine success stories, challenges in controlling 
infections, vaccine economics and financing, vaccine development 
and production in sub-Saharan Africa, critical operational issues, 
Decade of Vaccines / Global Vaccine Action Plan (GVAP), new 
vaccines, access, and closure. There were 36 plenary speakers, 20 
of whom hailed from Africa. Launching the conference, the Dean of 
the Faculty of Health Sciences at the University of Cape Town in 
South Africa, Professor Marian Jacobs said lack of access to 
immunisation is a denial of children's basic human rights. "The title 
International African Vaccinology Conference captures the spirit and 
intent of the gathering - to signal the urgent need to secure a global 
commitment to addressing the challenges to achieving universal 
childhood immunisation in Africa, she continued. All African 
countries (except Somalia) have ratified the Convention on the 
Rights of a Child, which reminds us of the legal entitlement of every 
African child to the right to survival, to universal access to health 
care, and especially to universal access to preventive measures such 
as immunisation. “So your vaccine efforts ... have to be 
underpinned by this value if we are to address the inequity which 
plagues immunisation access", she concluded. 
  
There was general acknowledgment that giant strides have been 
made since the global launch of the Expanded Programme on 
Immunisation in 1974. It is now estimated that about 2.5 million 
children are saved every year due to vaccines against infectious 
diseases. There has been substantial support and funding for low-
income African countries through mechanisms like the Global 
Alliance for Vaccines and Immunisation (GAVI), enabling countries 
to introduce new life-saving vaccines; but progress has been slow. 
Vaccine development has also advanced, with new vaccines being 
brought to the market and others in late stages of clinical trials. The 
time from registration of a new vaccine to introduction in low-
income countries has been significantly reduced, with the 
introduction of new pneumococcal and rotavirus vaccines in low-
income countries (with GAVI and industry support) occurring almost 
at the same time as in high-income countries. These vaccines 
prevent the leading causes of child mortality, namely: pneumonia 
and diarrhoea. We also have the new meningococcal A conjugate 
vaccine manufactured solely for use in the African meningitis belt. 
In December 2010, global health leaders committed to making the 
next 10 years the Decade of Vaccines - to ensure discovery, 
development, and delivery of life-saving vaccines globally, especially 
to the poorest countries. This culminated with the endorsement in 
May 2012 of the Global Vaccine Action Plan. In spite of all these 
initiatives, more than six million children remain incompletely 
vaccinated in Africa leading to more than one million deaths 
annually. This sub-optimal coverage had a huge impact on the 
inability of Nigeria to interrupt wild poliovirus transmission (until 
2014), with importation to other African countries. The lessons 
learnt from India (declared polio free on 25 February 2012), in 
interrupting wild poliovirus transmission, were presented. The main 
factors that delayed the interruption of transmission were an 
extremely high force of transmission, failure to vaccinate, and 
vaccine failure. The issue of low coverage and missed opportunities 
for vaccination was addressed by eight to nine campaigns annually 
for children under the age of five years, micro-planning of the 
campaigns to cover every household, and catching up with migrant 
children in transit. The failure of the trivalent oral poliovirus vaccine 
to induce adequate vaccine efficacy was addressed by the 
manufacture, testing, and introduction of mono valent and bivalent 
oral poliovirus vaccines. These vaccines are two to three times more 
effective than the trivalent vaccine. Although the Americas have 
eliminated measles, Africa still suffers frequent outbreaks due to 
poor coverage. African ministers of health passed a resolution 
calling for measles elimination by 2020, at the 61st session of the 
WHO Regional Committee for Africa. The first key milestone to be 
reached before achieving measles elimination is to ensure that all 
countries in the region reach 90% coverage with the first dose of a 
measles-containing vaccine at national level. The conference noted 
that African countries need to improve their immunisation 
programmes if they are to save lives. Delegates resolved to enhance 
immunisation programme performance by strengthening human 
resources at all levels, from the grass roots to the national health 
department; timely collection and reporting of immunisation data; 
monitoring and evaluation of programme performance; adequate 
vaccine supply chain management; surveillance of adverse events 
following immunisation; and laboratory surveillance of vaccine-
preventable diseases. It was strongly emphasised that it did not 
make good financial sense to introduce a new expensive vaccine 
into a dysfunctional immunisation system. 
  
There was also much interest in the promotion of research and 
development and production of new vaccines and technologies on 
the continent. There was agreement that Africa needs to start 
manufacturing vaccines in order to drive prices down and ensure 
supply, as a matter of urgency. Cuba, a country which is poorer 
than many African countries and which has also faced major 
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punitive sanctions, was lauded as an example for African vaccine 
manufacturers. Cuba is now self-sufficient in terms of vaccine 
production. African manufacturers were also called upon to take the 
initiative and manufacture the vaccines needed by Africans, for 
which there is a gap in the market, for diseases that are major 
problems in Africa and other low and middle-income countries. 
These include vaccines for TB, malaria, HIV, and neglected tropical 
diseases. Conference participants heard the latest developments in 
research on new TB, HIV, and dengue vaccines. The first 
announcement of the RTS,S malaria vaccine results in infants were 
presented. The vaccine was shown to be safe and although the 
vaccine efficacy of 30% is low; these results are encouraging in the 
quest for the first efficacious malaria vaccine. A strong emphasis 
was placed on (i) developing and promoting a vaccine advocacy 
action plan for Africa [8,9] in the Decade of Vaccines, to encourage 
more allocation of resources for vaccine initiatives on the continent; 
and (ii) finding ways of ensuring sustainable financing of vaccines at 
country level [2]. It was also highlighted that appropriate measures 
should be taken to ensure that immunisation services meet the 
needs of recipient communities and that service providers should 
work with communities to ensure their involvement and 
participation. The delegates noted that there is power in joint 
action, as can be seen from the ability of the Pan American Health 
Organization ((http://www.paho.org/) to negotiate low prices for 
new vaccines and to eradicate/eliminate infectious diseases like 
polio, measles, and rubella. Delegates thus committed themselves, 
in the Cape Town Declaration on Vaccines, to continually advocate 
for political will and to hold legislators to account for ensuring 
access to vaccines and functioning immunisation services during this 
Decade of Vaccines [1].The delegates committed themselves to 
advocate for sustainable financing for vaccines and immunisation 
programmes, including ring-fenced country budgets and innovative 
pooled pricing mechanisms to assist countries not eligible for GAVI 
support to access affordable vaccines. They would advocate for 
lower costs of immunisation programmes in Africa, perhaps through 
bulk buying and improved administration for rollout through the 
New Partnership for Africa´s Development (NEPAD). The delegates 
called for the integration of immunisation programmes into disease 
prevention programmes within a primary health care framework. 
They also recommended that immunisation programme 
performance be enhanced through strengthening human resource 
capacity at all levels; collection, collation and reporting of data; 
monitoring and evaluation; appropriate supply chain management; 
and strengthening of laboratories to provide quality surveillance for 
vaccine-preventable diseases. It was noted consistently throughout 
the conference that all efforts to improve vaccine access, delivery, 
and coverage will fail dismally without community involvement. 
Advocacy and communication efforts need to involve caregivers and 
patients. It is only by translating complex science into the language 
of those being vaccinated that the benefits and risks of 
immunisation will truly be understood. Delegates therefore, 
committed to effective communication and advocacy for 
immunisation at all levels of the health system as well as with 
traditional and faith leaders, civil society, and non-governmental 
organisations. Finally, the delegates confirmed their agreement with 
and commitment to the goals and strategic objectives of the GVAP 
and will hold African leaders responsible for its implementation. The 
conference was seen as useful by the attendees and their feedback 
in evaluating the conference was been overwhelmingly positive. The 
delegates recommended that the conference be held every two 
years. 
  
  
 
 
 
Conclusion 
 
The first International African Vaccinology Conference, held in 
November 2012 in Cape Town, was the first international 
vaccinology conference in Africa, for Africa, and about Africa. The 
conference focused on critical vaccine and immunisation issues for 
Africa and the world. The delegates were unanimous that they 
cannot stand by while African children do not get a simple 
intervention that saves lives and reduces suffering on the huge 
scale that immunisation does. Universal immunisation coverage 
would allow millions of African children to lead normal healthy lives 
and develop into healthy adults, free from vaccine-preventable 
disability and disease. 
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